Podcasts about Oncology

Season 5 Ep 2 - Anthony Fauci's Diary and Congressional Testimony by Plenary Session

Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer Society⁠National Cancer Institute⁠American Film Institute⁠ER (NBC)⁠50/50 (Official)⁠Chasing Life (ABC Family Archive)⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tonight on America At Night with McGraw Milhaven, it's another edition of MacFarlane Mondays as investigative journalist and MeidasTouch chief Washington correspondent Scott MacFarlane joins McGraw to break down the latest political developments from the nation's capital, offering insight into the biggest stories shaping Washington. Then, Dr. Cynthia Sears, Professor of Medicine, Oncology, and Molecular Microbiology and Immunology at Johns Hopkins University, discusses the growing Cyclospora outbreak, what Americans should know about the foodborne parasite, and the concerning social media trend known as "parasite maxxing," where some people intentionally expose themselves to parasites based on misleading health claims. Plus, author Joshua Kendall joins the program to discuss his latest book, Trudeau & Doonesbury, exploring the life and legacy of legendary cartoonist Garry Trudeau, the impact of Doonesbury on American politics and culture, and why the comic strip continues to resonate decades after its debut. Learn more about your ad choices. Visit podcastchoices.com/adchoices

When multiple loved ones are diagnosed with breast cancer within a short period of time, it can leave you wondering if, and when, it might become part of your own story. Megan May knew her family history meant that she was at greater risk of developing breast cancer. She prepared as best she could and underwent regular screenings. However, her diagnosis at age 40 still came as a shock because there are some things that no one can fully prepare you for. Megan is here today to share her story - how a series of family diagnoses prompted her to begin early screening, what it was like to hear the words no one wants to hear, and the physical and emotional challenges that followed. We'll talk about how why giving back through fundraising has become such an important part of her mission and how her family supports each other through it all. Key Takeaways Family history can help identify when earlier screenings are needed Early detection can allow cancer to be caught and treated quickly Supporting someone with cancer starts with simply being present Knowing your normal and getting screened can save lives Chapters 00:00 – Megan's family history with breast cancer 02:20 – Starting early screenings 04:04 – Megan's diagnosis and treatment journey 09:39 – Finding strength through movement and survivorship 14:46 – Supporting family and advocating for early detection Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

What do we do when the ground is unstable and information is incomplete? We are told to wait for the right conditions. But what if waiting costs more than acting? The real risk is failing to achieve your purpose.Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I chose this specific conversation because Marc is the one who speaks best about what execution requires when the context refuses to stabilize. Through his experience, I wanted to explore what it concretely costs to actually do what you said you would do. His answer is very simple: we trust the ground and move forward. It reveals that accepting certain departures, stopping certain projects, and changing directions are the necessary costs of executing with integrity. Marc Gailhardou (who has since been appointed President Intercontinental Region at MSD) brings this perspective from his role leading the EEMEA zone for MSD, while also serving on the board of the digital health startup The Resilience in Oncology. Tasked with managing a geographical area consisting of 25 percent of the world's population, his impossible context is one of permanent volatility. From maintaining operations across war zones to meeting the demands of emerging economies, he proves that long-term vision requires immediate, bold action. In this episode, we cover:◾️Leading Through Volatility : Managing safety, compliance, and operations across the diverse EEMEA region.◾️The Appetite for the Future : Why high-growth markets embrace bold strategies while mature markets hesitate.◾️Career as a Marathon : Moving out of your comfort zone, creating options, and knowing when it is time to transition.◾️Corporate to Startup : Gaining agility, speed, and new perspectives through board roles at organizations like The Resilience in Oncology.◾️Clarity Over Brutality : Focusing on the task rather than attacking the person to lead with respect.Execution without stability is rarely comfortable. It demands hard choices and decisive momentum. Clarity wins over caution every time.

In this episode, Dr. James McGee, Osf Healthcare Cancer Institute, discusses the urgent need to expand cancer prevention and early detection in rural communities while addressing the unique challenges rural providers face. He also shares his perspective on AI in oncology, the growing impact of obesity on cancer care, and emerging innovations that could improve access and reduce the cost of treatment.

"When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let's explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?" James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about addressing medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 31, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to medical trauma in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 421: Medical Trauma in Oncology Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse ONS Voice articles: Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD [post-traumatic stress disorder] Past Trauma Lowers Hope, QOL, and Coping Ability During Cancer Managing Cancer-Related PTSD Starts With Acknowledgement Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress Clinical Journal of Oncology Nursing articles: How Can a Trauma-Informed Care Approach Be Applied to Patients With Gynecologic Cancer? Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS course: Psychosocial Dimensions of Cancer Care™ ONS Huddle Card: Coping Screening tools Clinician-Administered PTSD Scale for DSM-5 [Diagnostic and Statistical Manual of Mental Disorders, 5th edition] (CAPS-5) Hospital Anxiety and Depression Scale Primary Care PTSD Screen for DSM-5 PTSD Checklist for DSM-5 Trauma Screening Questionnaire International Society for Traumatic Stress Studies: Free Resources PESI Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "For many people who have been traumatized, if they can avoid it, they will. They may not avoid the annual evaluation that is so hugely consequential—they might not avoid that. But they may well avoid a routine visit for a checkup to their oncologist. They very well may avoid a visit with a psychologist who is wanting them to talk about hard things. They may avoid visiting a friend in the hospital because it reminds them of really upsetting things. So, this issue of adherence and compliance is a really big problem." TS 3:19 "Screening tools for things like PTSD can be very useful. They're quite practical, and they're appropriate to use. I really like something called the Post-Traumatic Stress Disorder Checklist. ... Using it is going to be very straightforward. You're going to want to map it onto a 30-day window, and you're going to employ it with patients. It's a 20-item self-report. It assesses 20 DSM-5 symptoms of PTSD. It's not diagnostic, but if people score in this range of 30, 31, 33, we typically are going to believe that that is very suggestive of significant PTSD." TS 9:17 "One of the things we should be doing all the time is modeling and attempting to normalize this idea of being open about mental health difficulties. When I say modeling, this is a complicated issue. ... I'm very open talking about my own battles with mental health. And in some ways, that invites my patients to do the same. I don't recommend necessarily that a nurse says, 'Oh, by the way, I have PTSD. I'm going to tell you about mine. I want you to tell me about yours.' That's a boundary issue. But I think it does behoove us as clinicians to create a culture as much as we're able, where we can talk about mental health difficulties in a matter-of-fact way, acknowledging that mental health is health. These tools, to me, go a long way in that direction." TS 13:41 "The survivorship process is ongoing. I think a nurse can assist a patient in so many ways longitudinally over time. ... One of those ways is to continue checking on mental health outcomes in patients. Continuing to check on mental health outcomes, continuing to explore them, and continuing to invite patients to talk about things that other people might not be asking about. It's easy for family members to assume, 'Hey, you know, you're cancer free now. You look fine, so you must be fine.' It's very possible that the patients we're talking about are not fine. They're far from fine. For that oncology nurse at a follow-up clinic or in an oncology setting to talk about this, continuing to affirm that it would be okay for patients to struggle, continuing to put this issue on a front burner—I think that's really important." TS 21:17 "I'm aware of nurse-led support groups where nurses can talk very freely about their own challenges, in a safe space. ... Working to build cultures in the context of the intensive care unit, let's say, where we have a lot of patients with cancer that prioritize well-being nurse driven programs. ...  The bottom line is if there is a warning light that is blinking, nurses need to attend to that. And in attending to it, they're going to be more present for their patient. They're going to be better able to support their patient. They're going to be better able to support each other. And I think often, in the culture of nursing and psychology, too, people just put their head down, their shoulder down, and they just plow through in ways that are really counter to their mental health." TS 29:56 "The truth is medical trauma can be well-managed. It's not simple. It's not always intuitive. There are all sorts of caveats with regard to this, but the truth is people with medical trauma can live really rich and meaningful lives. ... So, the default setting, I think, should be not one of pessimism. It should be that people with medical trauma can and do get better. If you are a patient with medical trauma and you are in my purview, until proven differently, I'm going to assume that you can get better too." TS 36:28

In today's episode, we spoke with Solange Peters, MD, PhD. Dr Peters is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Switzerland. In our exclusive interview, Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in non–small cell lung cancer (NSCLC), rather than sequencing them. She noted that prior attempts to combine or sequence bevacizumab (Avastin) with checkpoint inhibitors yielded only modest signals, hampered by bevacizumab's long half-life and class-specific toxicities including bleeding risk that historically excluded patients with squamous cell carcinoma. By contrast, PD-L1/VEGF bispecifics such as pumitamig carry a significantly shorter half-life of approximately 5 to 6 days, resulting in a similar toxicity category but with lower rates of high-grade events and a broadened eligible population.She highlighted the mechanistic rationale for this combination, explaining that VEGF and PD-L1 co-targeting appears to remodel the tumor microenvironment cooperatively, bringing cancer cells into closer proximity with T cells. In the case of PD-L1/VEGF bispecifics, a macromolecular structure forms in the tumor microenvironment that leads to internalization of PD-L1, creating a dual blockade of the PD-1/PD-L1 pathway beyond simple receptor occupancy.Dr Peters then discussed data presented at the 2026 ASCO Annual Meeting from the phase 2/3 ROSETTA Lung-02 trial (NCT06712316) evaluating pumitamig plus chemotherapy in the first-line setting. She described the activity observed across all PD-L1 expression strata, including in PD-L1–negative patients, who comprised up to 70% of the nonsquamous population and achieved response rates above 50% as particularly compelling. She also addressed the dose selection rationale, noting that the 1500-mg dose demonstrated the optimal pharmacodynamic activity and favorable risk-benefit profile for phase 3 advancement.Finally, Dr Peters offered broader perspective on the increasingly competitive PD-L1/VEGF bispecific landscape, including the parallel development of ivonescimab. She suggested that differences in clinical trial design including patient population, inclusion and exclusion criteria, and end point ambition may ultimately differentiate agents more than mechanism alone, and emphasized that global data will be essential to shaping regulatory and clinical practice decisions.

Send us Fan MailIn this episode of the Life Science Success Podcast my guest is Stella Vnook. Stella is the CEO, Co-Founder, and Executive Board Chair at Kaida BioPharma, where she is advancing precision oncology therapies and bringing her experience as a serial biotech entrepreneur, investor, and life sciences leader to the future of cancer treatment.00:00 Welcome to the Podcast00:38 Meet Stella Vnook01:23 From Big Pharma to Startups04:58 Thriving as Startup CEO08:08 Mission Driven by Family10:27 Hard Lessons in Translation15:08 Building Kaida BioPharma18:12 Fundraising in a Tough Market22:33 De Risking and Milestones25:03 Faster to Clinic with Rigor29:12 Women Leading in Biotech35:47 Precision Medicine Outlook38:17 Inspiration and Concerns45:46 How to Connect and Wrap Up

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock. Of the hundreds of scientists Fraumeni mentored, perhaps one of the closest was Stephen J. Chanock, his successor as director of the NCI Division of Cancer Epidemiology and Genetics, who worked with Fraumeni for 25 years. Fraumeni died on June 22. He was 93. Otis Brawley, co-editor of the Cancer History Project and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, interviewed Chanock on the most recent episode of the Cancer History Project podcast. Brawley and Chanock looked back on Fraumeni's 50-year long career. His contributions to science included co-discovering the Li-Fraumeni syndrome and developing cancer maps, which visualize cancer rate data from every county in the U.S. His work served as a backbone for other major discoveries, such as the two-hit hypothesis by Alfred Knudson and BRCA genes.Fraumeni developed theories around how cancer works and tested them. “The mission statement of DCEG has been to understand the etiology of cancer through epidemiology and genetics as a means to prevention or early intervention,” Chanock said. “That's really the wisdom of Joe Fraumeni who lived that, and really developed the tools, the capabilities, and the workforce to pursue that.”As a result, Fraumeni established a vision of cancer's genetic susceptibility. His observations about diethylstilbestrol raised “a very revolutionary idea” that early exposures could result in precancerous conditions and develop into cancers decades later. The cancer maps added a new attention to cancer caused by environmental exposures. “These patterns were very important, which led to understandings about what was going on post-World War II and [how] certain occupations are associated with select cancers,” Chanock said. “This led to the birth of a whole set of cohorts and case control studies to look at asbestos, smelters, occupational hazards and smokeless tobacco use in the South.” The goal was always to help patients, many of whom had no options at the start of Fraumeni's career. “What Joe was envisioning was the more we understand, the more we can be honest and explain to our patients who develop cancer or may develop cancer, what we could be done to prevent or decrease that risk,” Chanock said. A transcript of this conversation, along with an archive of related content, is available on the Cancer History Project: https://cancerhistoryproject.com/article/joseph-f-fraumeni-jr/ 

In the newest edition of Oncology On the Go, Joshua Richter, MD, and Marco Davila, MD, PhD, spoke about the current multiple myeloma treatment landscape and highlighted practical considerations for administering CAR T-cell therapy to patients. Their discussion touched upon several critical subtopics ranging from optimizing operational and referral workflows to dismantling barriers to treatment access in rural settings.When it comes to navigating the multiple myeloma treatment algorithm, both hosts emphasized early evaluation to determine patient suitability for CAR T-cell therapy, which may help identify those who are most likely to experience the greatest responses with minimal toxicity. Regarding the question of sequencing different modalities, Richter pointed to data demonstrating the utility of administering CAR T-cell therapies prior to bispecific antibodies.Acknowledging that the average patient enrolled on a clinical trial may not align with what is typically seen in real-world practice, the hosts discussed “reassuring” data that those who do not meet certain eligibility criteria may nevertheless benefit from CAR T-cell therapy. Additionally, on the topic of maintaining an effective referral relationship between community oncologists and CAR-T centers, Davila noted that academic cell therapy clinicians may have an incumbent responsibility to consider how to improve access to treatment and make it easier for others to refer patients to care.“CAR T-cell therapy is now deeply entrenched in the world of relapsed multiple myeloma [and] soon to be likely entrenched in the newly diagnosed world. These are therapies that I think we're all going to need to embrace whether it's from an academic standpoint or a community standpoint,” Richter concluded. “Having that ongoing communication back and forth, especially as the field is moving so quickly, is absolutely key in providing optimal care for our patients.”Richter is an associate professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute, as well as the director of Multiple Myeloma at the Blavatnik Family - Chelsea Medical Center at Mount Sinai. Davila is the senior vice president and associate director for Translational Research, a professor of Oncology, chief of Lymphoma/Multiple Myeloma Service, and Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center.

In this podcast, 2 leading haematologists discuss the unmet needs in multiple myeloma in the second-line setting and beyond, considerations for treatment decisions, and the evolving treatment landscape with a focus on B-cell maturation antigen-targeted bispecific antibodies, a rapidly advancing class of treatments in this setting. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03715-z. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy" where the team was able to identify that ultra-low-burden FLT3-ITD microclones are associated with higher relapse risk and inferior relapse-free survival. Their work encourages the evaluation of FLT3 inhibitor strategies. Dr. Basu discusses "CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial". In four patients, the treatment was well tolerated and supported CAR T-cell expansion and persistence, challenging the need for lymphodepletion and supporting chemotherapy-free approaches in autoimmune disease.

In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Mel Moore interviews Dr. Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery, and specialising in minimally invasive thoracic surgery and pleural disease. Dr. Eckhaus discusses her extensive training and experience, groundbreaking work in robotic lung surgery, and her contributions to the development of the Binational Australian and New Zealand Thoracic Surgical Database. The conversation also explores Dr. Eckhaus' academic pursuits in clinical ethics at Oxford University and the practical implications for informed consent in surgical procedures. This episode provides an in-depth look into the evolving field of thoracic surgery, advancements in robotic technology, and the essential role of comprehensive data collection in improving patient outcomes. (00:00) Introduction and Acknowledgements (00:39) Meet Dr. Jazmin Eckhaus (01:52) Journey to Thoracic Surgery (04:57) Robotic Surgery Innovations (11:53) Thoracic Surgical Database (15:53) Clinical Ethics and Consent (26:19) Personal Interests and Conclusion Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with Arif Kamal, MD, Chief Patient Officer at the American Cancer Society (ACS). Dr. Kamal discusses his recent appointment to this inaugural role at ACS, leading into a conversation about how he expects the cancer care field to evolve. Namely, a shift for providers toward building a skillset for compassionate patient conversations, a shift toward self-administered treatment modalities whenever possible, and new payment models for multi-cancer early detection tests. Dr. Kamal also shares how ACS's recently launched Access to Clinical Trials and Support program—an education-forward initiative designed is helping to reduce the challenges and barriers patients face when enrolling in clinical trials. "When you think about...the goal of cancer care...it's about more and better days. It is a false choice to choose between one or the other...As we're getting people to the other side [of treatment], are we leaving them financially devastated, significantly lonely, without support around them?" – Arif Kamal, MD Arif Kamal, MD Chief Patient Officer American Cancer Society To submit a topic of discussion to the podcast, please email mark.liu@mountsinai.org and deirdre.saulet@hellojasper.com. The 2026 Oncology Unscripted series is exclusively sponsored by Advarra. Resources Spirituality and Cultural Humility: Core Components of Comprehensive Palliative Care Together As One: Advancing Joy, Resilience, and Peer Support in Oncology Care Oncology Unscripted: Transforming Palliative Care in Oncology

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics: Introduction (00:00) Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24) Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52) Adjuvant CDK4/6 Inhibitor Therapy (17:14) Practical Considerations with CDK4/6 Inhibitors (29:57) Monitoring and Management of Cytopenias (42:02) CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32) Management of Gastrointestinal Adverse Events (1:03:47) CDK4/6 Inhibitors in Unique Populations (1:10:41) Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48) CME information and select publications

A drug company that had been planning to remove a breast cancer and endometriosis medication from Australian shelves now says it will offer it for free to all patients who need it, indefinitely.

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode, we highlighted an OncLive Peer Exchange discussion about cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) moderated by Misty D. Shields, MD, PhD. Dr Shields is an assistant professor of clinical medicine in the Department of Medicine in the Division of Hematology/Oncology at the Indiana University (IU) School of Medicine, as well as an adjunct assistant professor of medical & molecular genetics and an associate member of Experimental and Developmental Therapeutics at the IU Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. She was joined by Triparna Sen, MD, PhD, MS, a professor at The Ohio State University in Columbus, and Ditte Primdahl, MD, an assistant professor of neurology (neuro-oncology) and neurological surgery at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.In this exclusive conversation, the experts discussed the ties between cancer-associated LEMS and small cell lung cancer. They noted that LEMS is characterized by proximal muscle weakness, hyperreflexia, and autonomic dysfunction, and that diagnostic challenges include late referral to neurology and misattribution of symptoms to cancer-related fatigue. They also highlighted key symptoms, which include proximal leg weakness, dry mouth, and blurred vision. Furthermore, they dove into treatment options for symptom control and emphasized that a multidisciplinary approach to care, including oncology, neurology, and laboratory medicine, is crucial for early LEMS diagnosis and effective management.

In today's episode, we spoke with Jorge E. Cortes, MD, and Elias Jabbour, MD. Dr Cortes is the chief of Hematology in the Division of Hematology and Oncology and the associate director for Translation at the UAB O'Neal Cancer Center in Birmingham, Alabama. Dr Jabbour is a professor of leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.In our exclusive interview, Dr Cortes and Dr Jabbour discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, they both discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, the two also shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm.

Denise Salem, Oncology Chaplain at Riverside Healthcare, explains how pastoral care adds an extra layer of support alongside medical treatment by providing a listening presence, spiritual resources when wanted, and practical help for families and staff. She describes outpatient chaplain visits at the Riverside Cancer Institute and infusion clinics in Bourbonnais, Watseka, Frankfort, and Coal City; the non‑proselytizing, faith‑inclusive nature of chaplaincy; and common issues addressed—including fear of the unknown, guilt, loneliness, and the modern problem of “cancer ghosting.” Salem shares examples of how caregivers and friends can show up—daily texts, group devotions, or small creative gestures—how chaplains help patients identify reasons to hope (trusted medical teams, future milestones), and why adaptability and meeting patients where they are are central to effective pastoral care.

Listen to JCO's Art of Oncology article, "He Was Always There" by Dr. Vangipuram Sai Shreya, who is a postgraduate resident in General Medicine at Sri Ramachandra Institute of Higher Education and Research in Chennai, India. The article is followed by an interview with Vangipuram and host Dr. Mikkael Sekeres. Dr. Vangipuram reflects on how not every patient is on the chart. LINK TO FULL TRANSCRIPT

Plus: Apple approaches $5 trillion market cap. And AstraZeneca says it's on track to hit its revenue target for 2030. Imani Moise hosts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join host Myrna Young as she delves into cancer care and treatments with Dr. Rohit Gosain and Dr. Rahul Gisain, the Oncology Brothers, board-certified hematologists and medical oncologists from New York. This episode explores separating medical facts from media hype, understanding complex cancer research, and addressing treatment disparities. Learn about breakthrough treatments, the importance of personalized medicine, and how informed decisions can impact outcomes. Whether you're a patient, caregiver, or healthcare enthusiast, gain valuable insights into navigating the evolving landscape of cancer care.The Oncology Brothers share their professional journey and why they chose to specialize in oncology and hematology. They discuss how fast-evolving cancer treatments are being communicated and documented at medical conferences and highlight the significance of unbiased perspectives when selecting the best treatment options. Myrna and the doctors also emphasize the importance of understanding screening guidelines and genetic mutations for personalized cancer treatment, discussing various cancer advances like targeted therapies and immunotherapy. This episode serves as an enlightening resource for anyone affected by cancer, offering both hope and practical advice.Key Takeaways:The Oncology Brothers emphasize the explosion of cancer research and development, pointing out the annual approval of new treatments, which brings hope despite the challenges of keeping up with this data.Conferences serve as vital platforms for cancer education, yet the reality of financial and bias conflicts in the healthcare industry necessitates informed and independent patient advocacy.Treatment personalization through genetic profiling and understanding patient-specific mutations are pivotal in tackling cancers more effectively and improving patient outcomes.Listeners are encouraged to seek knowledge on the available cancer treatments, understand screening guidelines, and engage in shared decision-making with healthcare providers for optimal cancer care.Despite disparities in healthcare access due to geographical and financial constraints, efforts are ongoing to make cutting-edge cancer treatments more widely available.Timestamp Summary0:00 Welcome & Introduction2:09 Understanding Cancer Education5:20 Conversations Around Cancer Treatments10:14 The Role of Medical Conferences15:09 Recent Advancements in Cancer Treatment24:39 Patient Advocacy and Treatment Questions31:09 Disparities in Cancer Treatment Access42:31 Closing Remarks and ResourcesResources:OncBrothers WebsiteOncBrothers Podcast on YouTube | Spotify | Apple PodcastsSocial Media: @ONCBrothers on X/TwitterSponsors for this Episode SquareSquare brings payments, POS, inventory, staffing, and online sales together in one system – so business owners don't have to juggle a bunch of tools. Right now, listeners can get up to $200 off Square hardware when you sign up at square.com/go/transformQuinceQuince is not just apparel. Quince also offers elevated essentials for your home, from bedding and bath, to kitchen essentials and furniture.Make your summer wardrobe feel easier. Go to Quince.com/tym for free shipping on your order and 365-day returns Link to Transcript https://www.buzzsprout.com/1761155/19533950-oncology-advances-inside-the-latest-breakthroughs-in-cancer-treatment/transcriptSee this video on The Transform Your Mind YouTube Channel https://www.youtube.com/@MyhelpsUs/videosTo see a transcripts of this audio as well as links to all the advertisers on the show page https://myhelps.us/Follow Transform Your Mind on Instagram https://www.instagram.com/myrnamyoung/Follow Transform Your mind on Facebookhttps://www.facebook.com/profile.php?id=100063738390977Please leave a rating and review on iTunes https://podcasts.apple.com/us/podcast/transform-your-mind/id1144973094Feedspot Top 100 Mental Health Podcast For sponsored Brand interviews and sponsorship inquires please visit Partner With The Transform Your Mind Podcast | Myrna Young Life Coach

Disability and breast cancer intersect in more than one direction. Some people develop long-term effects like lymphedema, neuropathy or cognitive changes because of treatment — effects recognized as disabilities under the Americans with Disabilities Act. Others are already living with a disability, of any kind, when a breast cancer diagnosis enters the picture. This July, in recognition of Disability Pride Month, Krista Park Berry, Director of Susan G. Komen's Breast Care Helpline, returns to Real Pink to talk about how the Helpline supports people through their breast health experience no matter when their disability started, and what that support looks like for women of color in particular. Key takeaways No two disability experiences are the same Disability can exist before or develop after breast cancer treatment The Komen Breast Care Helpline provides personalized support and resources Accessible, whole-person care improves quality of life and health outcomes Chapters 00:00 – Understanding disability and breast cancer 02:08 – Treatment-related disabilities and ADA protections 06:26 – Supporting people living with metastatic breast cancer 08:11 – Navigating breast cancer with a pre-existing disability 12:11 – Health equity, women of color, and closing care gaps 13:36 – Why asking for help can change everything

At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at the meeting covered practical considerations for integrating CAR T-cell therapies, bispecific antibodies, and other modalities into the treatment of those with multiple myeloma, lymphoma, and other hematologic malignancies.First, Benjamin Diamond, MD, an assistant professor of Clinical Medicine, a member of the Sylvester Myeloma Institute, and a member of the Myeloma Genomic Lab at the University of Miami Miller School of Medicine, spoke about his presentation reviewing bispecific antibodies for the management of multiple myeloma. In his session, Diamond stated that bispecific T-cell engagers are altering the landscape of multiple myeloma care and will eventually become an option in the frontline setting. With many products to choose from, Diamond emphasized sequencing these novel therapies wisely and stressed aggressive infection prophylaxis as a mandatory facet of care.Next, Tiba Al Sagheer, PharmD, BCOP, BCACP, a pharmacy quality improvement coordinator for transplant and cellular therapy at Miami Cancer Institute of Baptist Health South Florida discussed her presentation focused on defining new thresholds for monitoring and mitigating toxicities associated with CAR T-cell therapy. She described considerations for balancing early toxicity intervention against the risk of blunting efficacy depending on the specific CAR T-cell product used during treatment. Ultimately, she noted that that there is still no definitive answer or threshold for initiating prophylaxis for toxicity associated with CAR T, and that differentiating between immune effector cell (IEC)–associated hemophagocytic lymphohistiocytosis (HLH)–like syndrome (IEC-HS) and cytokine release syndrome (CRS) represents an ongoing challenge in the field.Finally, Nikesh N. Shah, MD, and Carlos Silva Rondon, MD, shared their perspectives on a debate regarding the roles of bispecific antibodies and CAR T-cell therapies in relapsed/refractory follicular lymphoma. In his presentation, Shah, a hematologist-oncologist at Tampa General Hospital who specializes in hematologic malignancies, including aggressive lymphomas and acute lymphoblastic leukemia, took the position that bispecific antibodies should be used prior to CAR T-cell therapy for most patients, although both treatments have utility in the field. Silva Rondon, a hematologist, oncologist, and bone marrow transplant specialist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System/Memorial Cancer Institute in Pembroke Pines, advocated for CAR T-cell therapy during the debate but acknowledged that both modalities can make up a complementary strategy for overcoming relapsed/refractory follicular lymphoma.References Diamond B. Bispecific antibodies for the management of multiple myeloma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Sagheer TA. Thresholds and therapeutics: a precision approach to CAR T toxicity management. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Shah N. Debate: bispecific antibodies vs CAR-T in follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Silva C. CAR-T cell therapy for relapsed follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL.

Send us Fan MailIt's that time of year again, ya'll. The Little Legends Lemonade stand is back and better than ever, baby!For the third year, The Keri Croft show & Little Legends Lemonade are teaming up to bring kids, families, local businesses, and our entire community together to raise money for a great cause. This year, it's CancerFreeKIDS and  our goal is a big one: raise $5,000 in two hours to help fund the early-stage pediatric cancer research that can become tomorrow's life-saving treatments.Leading up to the event, The Keri Croft Show is releasing a special five-part series exploring the impact CancerFreeKIDS is having on pediatric cancer research, how new treatments actually make their way from an idea in a lab to a child's bedside, and why this work should matter to every single one of us.In this first episode, Keri sits down with Ellen Flannery, founder of CancerFreeKIDS, and Dr. Timothy Cripe, Chief of the Division of Hematology, Oncology & Blood and Marrow Transplant at Nationwide Children's Hospital.Ellen shares the deeply personal story that led her to create CancerFreeKIDS after her infant daughter's cancer diagnosis. Dr. Cripe breaks down, in terms anyone can understand, why early-stage research is so critical, how groundbreaking ideas become real treatments, and what becomes possible when researchers receive the funding needed to take a chance on something new.Childhood cancer remains the leading cause of disease-related death for children in the United States, yet pediatric cancer research receives only a fraction of the funding it needs. This conversation explains the gap, the progress being made, and the very real role our community can play in moving that progress forward.

In this episode, Jordan Johnson, MSHA, Bridge Oncology, ABA Health Law Oncology Advocacy, discusses the major CMS policy shifts reshaping oncology, the growing role of AI governance, and why healthcare leaders must think beyond reimbursement rates to prepare for the future of care delivery. He also shares advice for entrepreneurs on building systems thinking across finance, clinical care, compliance, and technology.

Send us a message!Thinking about a career in oncology or dreaming of starting your own private practice? In this episode, our guest Christina DiSegna, MS, RD, CSO, CNSC, LDN, oncology & private practice dietitian, shares her career journey, advice for aspiring dietitians, and practical tips for building a fulfilling career while maintaining work-life balance. Christina DiSegna, MS, RD, CSO, CNSC, LDN, is a senior dietitian, a board-certified oncology specialist and a board-certified nutrition support clinician. She received her undergraduate degree at Boston College, post-graduate degrees from Tufts University and Simmons College, and completed her dietetic internship at Brigham and Women's Hospital.She has worked in clinical nutrition at Brigham and Women's Hospital and as a cancer care specialist at Dana-Farber Cancer Institute. She also owns a private practice, Christina, RD, where she works with a variety of clients to help them achieve their best and healthiest lives through better relationships with food.Interested in learning more? Contact Christina at christina@christinard.com and visit her website https://christinard.com/about/ .Check out our blog post on oncology resources: https://www.danajfnutrition.com/post/favorite-resources-for-oncology-dietitians

This story is about Lindsay Williams' and her reinvention From Olympic Burnout to Elite athlete and coach.By 2006, Lindsay Williams had already stood on the biggest stage in her sport. A Team USA Nordic skier at the Winter Olympics in Turin. But behind the accomplishment was exhaustion. Years of grueling training had burned her out completely, and she walked away from the sport that defined her identity. What came next wasn't a straight line back to glory.It was a total reinvention. Lindsay dove headfirst into the food service industry, building a career as a sous chef, all while quietly keeping her body moving through runs with her dog and backyard plyometric work. But it was the industry itself, late nights out with coworkers, a lifestyle drifting further from the athlete she used to be that delivered her wake up call.It came in an unlikely place: doing pull-ups in a workout class, feeling that old fire flicker back to life. That moment sparked a full return to her athletic drive. She turned to CrossFit  and Hyrox, which has led her to becoming one of the best in the country at both. This episode is about what happens when you let go of who you were to rebuild who you're becoming. You can follow Lindsay Williams on Instagram. Support the Minnesota Oncology program here: MN EXERCISE ONCOLOGY PROGRAMKeep your eyes out for Sharp in 24, my new podcast series debuting in the month of June. No fluff or filler, simply 24 minutes of high end knowledge and stories with experts who solved life's puzzle with reckless abandon and attention to detail.If something hit different today, find Jesse at Jesse Velasquez-Nutrition and fitness expert (@jcvwellness) • Instagram photos and videos Please subscribe and REVIEW this podcast where you listen to it!https://podcasts.apple.com/us/podcast/unplugged-and-undeniable/id1549489545https://www.iheart.com/podcast/966-unplugged-and-undeniable-76471120/This is where the community lives.

Holistic, integrative, functional, precision—the labels are everywhere, but few patients or clinicians know where one ends and the next begins.

Featuring perspectives from Dr Bradley J Monk, Dr David M O'Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O'Malley, including the following topics: Introduction (00:00) Overview of Ovarian Cancer (OC) (2:12) Role of PARP Inhibitors in Advanced OC (4:56) Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45) Role of Relacorilant in Advanced OC (57:08) Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first report from the CHORUS registry for hereditary hemorrhagic telangiectasia (HHT) presented by Dr. Al-Samkari and also the introduction of the ASH Hematomics (ASHOP) platform for integrative genomic data analysis presented by Dr. Zhou. The CHORUS registry reveals that HHT is a progressive, underrecognized inherited bleeding disorder with a substantial burden of recurrent bleeding, iron deficiency, arteriovenous malformations, and life-threatening complications, while emphasizing the need for earlier diagnosis and the development of targeted therapies. The second presentation introduces ASHOP, an open-access platform that enables researchers to explore and integrate large-scale clinical and genomic datasets, facilitating discoveries in leukemia and other hematologic diseases through advanced analytical tools. Together, these studies demonstrate how comprehensive patient registries and innovative data-sharing resources are advancing precision medicine, improving disease understanding, and accelerating future research across hematology.

Send us Fan MailDr. Kendra Pope shares how integrative veterinary oncology can help pet parents take a proactive approach to canine cancer prevention. Learn about nutrition, at-home health testing, wellness, veterinary costs, and why caring for the whole dog matters.CHAPTERS:Navigating the growing world of at-home test kits with Dr. Kendra Pope (0:55)Why wellness is more than physical, and why letting "dogs be dogs" matters (4:54)How Dr. Pope navigates oncology care while sometimes challenging "conventional" thinking, such as what to feed dogs (16:59)How pet parents can learn from Dr. Pope to take a proACTIVE approach to cancer prevention, the mindset shift needed and how to prioritize your efforts (27:44)Integrative care expands the veterinary toolbox beyond "conventional" treatment and why more young veterinarians aren't entering integrative medicine sooner (43:13)The growing impact of veterinary costs on cancer treatment decisions (49:10)The best part of Dr. Pope's job (56:38)LINKS DISCUSSED:Pet Cancer Risk Quiz - https://prismpets.krtra.com/t/NchL8dYAWUrKHow to Build a Cancer Resilient Pet Masterclass - https://prismpets.krtra.com/t/kXqbO9hPmQdTPet Cancer Prevention Course (Waitlist) - https://prismpets.krtra.com/t/IXdjgvPkLhZaPoppy Phillips with Dr. Pope (https://youtu.be/WQAx3AChAq0?si=WAHUneLXxDpKkoFz)Believe in Dog Podcast with Kim Brophey (https://believeindogpodcast.com/episodes-1/episode133)SOCIAL MEDIA:Kimberly: Raw Feeder Life, RawFeederLife.comErin Scott: Believe in Dog podcast, BelieveInDogPodcast.comRaw Feeder Life, Instagram.com/RawFeederLifeBelieve in Dog Podcast, Instagram.com/Erin_The_Dog_MomThanks for listening to our podcast.  You can learn more about Erin Scott's first podcast at BelieveInDogPodcast.com.  And you can learn more about raw feeding, raising dogs naturally, and Kimberly's dogs at KeepTheTailWagging.com.  And don't forget to subscribe to The Alternative Dog Moms.

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient leadership, and a deep understanding of unmet patient needs. In this engaging conversation, Rahul Chaturvedi sits down with Robert Jacks, President & CEO of Sparrow Pharmaceuticals, to explore his unconventional journey from civil engineering to biotech leadership, the lessons learned from building and exiting successful companies, and why creating lasting value should take precedence over chasing acquisitions. Robert reflects on his career spanning Pfizer, entrepreneurship, venture capital at OrbiMed, and leading multiple biotech companies, sharing how his experiences shaped his approach to leadership, capital allocation, and company building. He explains why influence matters more than authority, how empathy creates stronger organizations, and why keeping biotech companies lean allows them to remain resilient throughout unpredictable funding cycles. The conversation then explores Sparrow Pharmaceuticals' evolution from a rare disease company into a precision medicine leader focused on difficult-to-control type 2 diabetes. Robert provides an in-depth look at the emerging science behind cortisol biology, HSD1 inhibition, and why excess intracellular cortisol may represent one of the industry's most overlooked drivers of metabolic disease. He also discusses Sparrow's recent clinical data, the rationale behind its strategic pivot, the future of patient stratification in cardiometabolic disease, and how Sparrow aims to complement—not compete with—the rapidly expanding GLP-1 landscape. From fundraising and leadership philosophy to clinical development strategy and the next frontier of precision medicine, this episode offers practical insights for biotech founders, investors, and industry leaders navigating the complexities of building enduring biotech companies. Biography: Robert has 25 years of experience in the biopharmaceutical industry. He has founded or co-founded multiple companies and raised more than $300 million. Previously, Robert was the President & CEO of Indalo Therapeutics, a clinical-stage biotechnology company developing therapeutics for serious fibrotic diseases, and President, CFO, and Co-Founder of Symbiomix Therapeutics, which was sold after achieving NDA approval for Solosec®. Robert also previously held the positions of Head of Corporate Development for Tobira Therapeutics, Head of Business Development for ACT Biotech, and Entrepreneur-in-Residence for OrbiMed Advisors. Robert began his pharmaceutical industry career in finance and product development at Pfizer, where he last worked as the Director of Business Development for Oncology and Infectious Diseases. Robert earned an MBA from Columbia Business School, an MSE in Civil Engineering from Stanford University, and a BSE in Civil Engineering from Duke University. When not solving intractable healthcare problems, Robert spends as much time as possible with his two daughters.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partnership is set to harness artificial intelligence and machine learning technologies to revolutionize drug discovery and development. By enhancing data analysis and predictive modeling, this collaboration may lead to more efficient identification and validation of drug targets, reflecting a growing industry trend towards leveraging AI to streamline R&D processes. In infectious diseases, Gilead Sciences and Merck & Co. have reported promising phase 3 clinical trial results concerning their combination therapy for HIV treatment. This regimen, combining islatravir and lenacapavir, could become the first weekly oral medication for HIV, offering a significant improvement over daily treatments. Such developments not only promise enhanced patient adherence but also mark a pivotal step forward in long-term HIV management by potentially increasing quality of life for patients. Oncology diagnostics are also seeing significant strides as Tempus AI plans to acquire Personal Genome Diagnostics for $1.5 billion. This acquisition is poised to bolster Tempus's portfolio in cancer minimal residual disease diagnostics. The integration of capabilities from Personal Genome Diagnostics is expected to enhance precision oncology efforts, providing more comprehensive data for personalized cancer treatment plans. Regulatory updates bring more promising news with Takeda's dengue vaccine, Qdenga, securing approval in India. This live-attenuated vaccine targets all four serotypes of the dengue virus, representing a major advancement in regions burdened by dengue fever. Similarly, JCR Pharmaceuticals has received marketing authorization in the UAE for Izcargo, an enzyme replacement therapy that penetrates the blood-brain barrier to treat Hunter syndrome, showcasing innovations in treating rare genetic disorders. Strategic partnerships continue to be a focal point in industry growth. Menarini Asia-Pacific has joined forces with Pharmacosmos to commercialize Cosela across Asia-Pacific regions. Additionally, Halozyme Therapeutics has partnered with Incyte on subcutaneous formulations of a monoclonal antibody using their proprietary Enhaze technology, highlighting advancements in drug delivery systems. Financially, Novartis has shown resilience by returning to sales growth driven by products like Kisqali and Kesimpta amidst generic competition challenges. Meanwhile, Axiom Biosciences is gearing up for an IPO in Hong Kong, indicating a growing interest in stem cell therapies for neurological and rare diseases. Yet not all news has been positive. Novartis has discontinued its phase 2 radioligand therapy targeting gastrin-releasing peptide receptors due to underwhelming results in solid tumors. Agios Pharmaceuticals has similarly halted development of its pyruvate kinase activator for sickle cell disease following unsatisfactory phase 2 data. Legal battles continue as well, with Novo Nordisk suing Eli Lilly over GLP-1 agonists efficacy claims and Moderna locked in patent disputes with CureVac over COVID vaccine technologies. These stories reflect dynamic shifts emphasizing innovation through AI collaborations and novel therapeutic developments in HIV and oncology treatments. They also highlight strategic acquisitions enhancing diagnostic capabilities while revealing challenges such as competitive pressures and regulatory hurdles that companies must navigate. Turning our attention back to scientific breakthroughs, Jennifer Doudna's venture into AI-powered protein design underscores how artificial intelligence continues transforming biotechnology. Her exploration highlights AI's potential to accelerate drug discovery by enabling more precise targeting of disease-related proteins. Additionally, recent successes in personalized medicine include the establishment of a new center dedicated to genetic therapies. Spearheaded by leading scientists, this initiative aims at developing tailored treatments based on individual genetic profiles—advancing precision medicine and reducing adverse effects. In conclusion, these developments illustrate a vibrant landscape where scientific breakthroughs intersect with strategic business maneuvers. As companies navigate these complex waters—balancing innovation with regulatory scrutiny—they continue pushing boundaries that promise improved patient outcomes worldwide while reshaping future healthcare landscapes.Support the show

Reboot - I am back with Audio podcasts by Plenary Session

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Oncology is simultaneously one of healthcare's greatest success stories and one of its biggest financial challenges. Cancer care continues to benefit from breakthroughs in precision medicine and early detection, even as oncology spending is projected to approach $200 billion by 2029. At the same time, cancer programs are facing rising patient volumes, growing demand for advanced therapies, and mounting pressure to improve access and affordability. In this episode, hosts Abby Burns and Chloe Bakst welcome oncology expert Gaby Marmolejos to break down the trends shaping cancer care in 2026 and beyond. Together, they explore improvements in community-based access to advanced therapies, the promise of multi-cancer early detection testing, and the reimbursement challenges threatening program sustainability. We're here to help: Playbook | Cell and gene therapy programs: How to launch, optimize, and deliver CGTs sustainably Roundtable referenced | Advisory Board Oncology Roundtable: Trends and tech you can't ignore Webinar | The top 4 trends in oncology today Report | Prioritizing equity in cancer treatment: Emerging ideas Episode | 270: Service line snapshot: What every health leader needs to know Episode | Ep. 209: Predicting what oncology will look like in 2030 Help shape Advisory Board's next research agenda by taking our quick survey — share your priorities and challenges to ensure our research reflects what matters most to healthcare leaders like you. A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Send us Fan MailYou've spent months mastering oncology content — but on exam day, just knowing the material isn't enough. The ABPTS Oncology Specialty Exam is a six-hour endurance event, and without a pacing strategy, smart break habits, and a system for beating distractors, even the most prepared PTs lose easy points. This episode gives you the exact test-day tactics to turn your knowledge into a passing score.The content lives in your brain. Now let's make sure it survives the exam room.⚡ In this episode, you'll learn:The Endurance Mindset — why exam day is a marathon, not a knowledge quiHow to break a 6-hour exam into four 90-minute "mini-battles" you can actually winThe 100-Second Rule — your pacing strategy for every single questionWhy flagging and moving on is the difference-maker for banking easy pointsThe "Cover Your Answers" technique — beat distractors before they beat youHow to formulate your answer BEFORE you ever see the choicesThe Break Protocol — why skipping your breaks is self-sabotage, and what to actually do during themFueling for six hours — what to eat the night before, morning of, and duringHydration strategy — sip, don't chugThe full exam-day timeline, from arrival to final click

Disclaimer: The views expressed by my guest are their own. This interview is for informational and educational purposes only and should not be considered medical advice. Please do your own research and consult a qualified healthcare professional before making medical decisions.Cancer has long been viewed through the lens of genetics, but what if one of the most widely accepted theories is missing a much bigger piece of the puzzle?In this conversation, researcher and author David Rasnick shares why he believes chromosomal imbalance—not gene mutations—is the driving force behind cancer.We discuss the work of Theodor Boveri, why this theory has remained outside the medical mainstream, the role of spontaneous remission, fever therapy, Coley's toxins, glycolysis, and the Warburg Effect, as well as why David believes understanding how cancer develops over time is critical to finding better approaches.David also discusses why many conventional cancer treatments appear to work initially before cancer returns, and explains his perspective on the body's natural ability to recognize and eliminate abnormal cells. Throughout our conversation, he challenges long-held assumptions and encourages listeners to examine the scientific literature for themselves.This Ke Ala Side version includes the portions that were edited or muted from the public YouTube release. If you'd like to hear the complete extended interview with additional discussion, it's available on The Plus Side.Learn more about David Rasnick: https://davidrasnick.comBUY A COFFEE LINK Support the Show & Stay Connected:Buy Me a Coffee: https://buymeacoffee.com/sensiblehippieJoin My Patreon for ad-free episodes & exclusive content:https://Patreon.com/WakeupwithMiyaIf you're joining Waiola – The Plus Side, please subscribe through a web browser (Safari or Chrome) instead of the Patreon app — it directly supports the show.Mahalo nui loa for supporting independent work and helping keep this platform growing.Shop my Amazon Storefront: https://www.amazon.com/shop/profile/amzn1.account.AGYOPCXXGH6MN5RVAKGQWVZUZLEA/list/26B87RB4FZ9W2?ref_=cm_sw_r_cp_ud_aipsflist_6BWRT43TH4MY2NM2XD6XWant to be on the show or suggest a guest? I'm looking for guests who can speak on human trafficking, the paranormal, occult symbolism, hidden history, spiritual warfare, ancient mysteries, and specific military stories involving covert operations, secret programs, psychological warfare, unexplained events, and firsthand accounts.Email me at: Miya@wakeupwithmiya.comFollow Me Online:Instagram: https://www.instagram.com/WakeupwithMiyaFacebook: https://www.facebook.com/WakeupwithMiyaExclusive Discount!Shop at LVNTA:https://lvnta.com/lv_IcTq5EmoFKaZfJhTiSUse code OHANA for 20% off!Listen on Your Favorite Platform: Spotify, Apple Podcasts, YouTube, and everywhere podcasts are available!RATE & REVIEW: Apple: https://podcasts.apple.com/us/podcast/wake-up-with-miya/id1627169850 Spotify: https://open.spotify.com/show/0UYrXCgma1lJYzf8glnAxyMusic Credits:Beginning: "Echoes in the Shadows" - DKEnd Music: “Crazy” - EkoBecome a supporter of this podcast: https://www.spreaker.com/podcast/wake-up-with-miya--6339129/support.

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology. Key Topics Covered: • ALK-positive lung cancer • Cellular Therapy • Vaccines Guests: Vincent Lam, MD Associate Professor of Oncology, Johns Hopkins University School of Medicine Director, Thoracic Oncology Clinical Research Program Sidney Kimmel Comprehensive Cancer Center Carmen Mecca. PhD Postdoctoral Fellow, Chiarle Lab Department of Pathology Boston Children's Hospital

Artificial Intelligence is buzzy. There's a lot about it in the news and a lot we think we understand about how to use it and a lot we may not fully understand. But the promise it holds is tremendous, and today we're going to learn a little more about how it could benefit breast cancer research and patient care in the near future. Drs. Charles Perou at UNC Chapel Hill and Erika Crosby at Duke University are two very accomplished breast cancer researchers who are joining us today to share their perspectives on using AI now and in the future. Key takeaways AI is improving breast cancer screening and diagnosis. Researchers are using AI to save time on coding, writing, and data analysis. AI can help match patients to clinical trials more effectively. Human expertise is still needed to verify AI-generated results. AI has the potential to accelerate research and improve patient care. Chapters 00:00 — Introduction to AI in Breast Cancer Research 02:53 — Ethical Considerations and Responsible AI Use 04:33 — Current Clinical Applications of AI 08:12 — How Researchers Are Using AI in the Lab 11:17 — AI Limitations, Mistakes, and Critical Thinking 17:23 — The Future of AI-Assisted Cancer Research Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. Michael Nolan, the Randall B. Terry Jr. Distinguished Professor of Oncology at North Carolina State University and a board-certified veterinary radiation oncologist. Dr. Nolan discusses how advances in radiation technology have transformed cancer treatment, from precisely targeting challenging tumors to exploring how radiation can enhance immunotherapy. The conversation also dives into his pioneering research on the connection between pain, the nervous system, and cancer biology, and how these discoveries could improve both patient comfort and cancer outcomes. Finally, Dr. Nolan shares promising early work combining radiation with novel targeted therapies for feline oral squamous cell carcinoma and offers insight into why pursuing overlooked research questions often leads to the biggest breakthroughs.

In this episode, Theodoros Teknos, MD, President & Scientific Director of University Hospitals Seidman Cancer Center and the Jane and Lee Seidman Chair in Cancer Innovation, discusses the importance of recruiting top oncology talent, balancing research with clinical care, and using AI to improve patient outcomes. He also shares why continued investment in cancer research and scientific discovery is critical to accelerating the next generation of cancer breakthroughs.

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications

We love to hear from our listeners. Send us a message.Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision medicine is headed as researchers pursue more effective treatments for patients with difficult-to-treat solid tumors, and more.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary teams must prioritize collaborative workflows at all points of the treatment journey. In this episode, CANCER BUZZ speaks with Manojkumar Bupathi, MD, President of Rocky Mountain Cancer Centers, about how ADCs are reshaping the care model toward earlier, structured collaboration between urology and medical oncology. Guests: Manojkumar Bupathi, MD President Rocky Mountain Cancer Centers Co-Chair, GU Executive Committee Sarah Cannon Research Institute Denver, CO "The challenge wasn't learning the drug itself. The challenge was how you integrate the regimen into your treatment paradigm." —Manojkumar Bupathi, MD "There's always this relationship that happens from the beginning and is maintained throughout the entire process." —Manojkumar Bupathi, MD Resources: ACCC Bladder Cancer Resources ACCC Antibody-Drug Conjugate Resources  

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We know that clinical trials are a critical lifeline, offering new ways to prevent, detect, diagnose and treat breast cancer. Today, patient advocates are transforming clinical trials by bringing the real-world experiences of patients directly to researchers. By acting as a bridge between science and the community, patient advocates boost enrollment in clinical trials, and help build a lasting trust Today we are speaking with Dr. Lior Braunstein, a radiation oncologist and researcher at Memorial Sloan Kettering Cancer Center, and Dr. Ellen Landsberger, a retired OB-GYN and patient advocate, also at Memorial Sloan Kettering Cancer Center. Together they are working on the ARCHER clinical trial, a study that is investigating a new treatment strategy for HER2-positive metastatic breast cancer. We'll talk about what they are hoping to accomplish through the ARCHER trial, what their collaborative process looks like and how patient advocates in clinical trials can help improve patient outcomes. Key Takeaways: Patient advocates help design better clinical trials The ARCHER trial aims to improve treatment outcomes Patient voices shape research from the very beginning Clinical trials study both treatment and quality of life Better access helps more patients join clinical trials Chapters 00:00:00 – Why patient advocates belong at the clinical trial design table 00:04:44 – From breast cancer survivor to patient advocate 00:07:46 – How advocates shape research and address patient concerns 00:12:08 – Inside the ARCHER trial and its goal to improve metastatic breast cancer treatment 00:19:03 – Measuring quality of life and improving access to clinical trials 00:26:28 – How patients can become advocates and influence future research